JP2023550543A5 - - Google Patents

Info

Publication number
JP2023550543A5
JP2023550543A5 JP2023551946A JP2023551946A JP2023550543A5 JP 2023550543 A5 JP2023550543 A5 JP 2023550543A5 JP 2023551946 A JP2023551946 A JP 2023551946A JP 2023551946 A JP2023551946 A JP 2023551946A JP 2023550543 A5 JP2023550543 A5 JP 2023550543A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057563 external-priority patent/WO2022094400A1/en
Publication of JP2023550543A publication Critical patent/JP2023550543A/ja
Publication of JP2023550543A5 publication Critical patent/JP2023550543A5/ja
Pending legal-status Critical Current

Links

JP2023551946A 2020-11-02 2021-11-01 二環式化合物及び疾患の治療のためのその使用 Pending JP2023550543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02
US63/108,660 2020-11-02
PCT/US2021/057563 WO2022094400A1 (en) 2020-11-02 2021-11-01 Bicyclic compounds and uses thereof for the treatment of diseases

Publications (2)

Publication Number Publication Date
JP2023550543A JP2023550543A (ja) 2023-12-01
JP2023550543A5 true JP2023550543A5 (https=) 2024-11-06

Family

ID=81384389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551946A Pending JP2023550543A (ja) 2020-11-02 2021-11-01 二環式化合物及び疾患の治療のためのその使用

Country Status (12)

Country Link
US (1) US20240025903A1 (https=)
EP (1) EP4236944A4 (https=)
JP (1) JP2023550543A (https=)
KR (1) KR20230104191A (https=)
CN (2) CN119684295A (https=)
AR (1) AR124637A1 (https=)
AU (1) AU2021371026A1 (https=)
CA (1) CA3196582A1 (https=)
CL (2) CL2023001195A1 (https=)
IL (1) IL302465A (https=)
MX (1) MX2023004942A (https=)
WO (1) WO2022094400A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240121239A (ko) * 2021-12-17 2024-08-08 아티라 파마, 인코포레이티드 질환 치료를 위한 이환식 화합물의 용도
EP4518864A1 (en) * 2022-05-04 2025-03-12 Athira Pharma, Inc. Methods of treating neuropathies
JP2025515045A (ja) * 2022-05-04 2025-05-13 アティラ・ファーマ・インコーポレイテッド 神経炎症病態を治療する方法
EP4618996A1 (en) 2022-11-18 2025-09-24 Athira Pharma, Inc. Methods of treating inflammatory conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
AU2005289560A1 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
CN102186853A (zh) * 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
WO2014025832A1 (en) * 2012-08-06 2014-02-13 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2017047762A1 (ja) * 2015-09-18 2017-03-23 国立大学法人鳥取大学 低分子化合物による癌と線維化の抑制と再生促進の効果

Similar Documents

Publication Publication Date Title
JP2023550543A5 (https=)
CA2505195A1 (en) Quinazolinones as potassium channel modulators
JP2020502092A5 (https=)
RU2019131111A (ru) ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
RU2009132189A (ru) Новые 2-аминооксазолины в качестве лигандов taar1
CA2441565A1 (en) Bisarylamines as potassium channel openers
JP2014051526A5 (https=)
JP2012515166A5 (https=)
JP2016534134A5 (https=)
JP2018502912A5 (https=)
JP2018505898A5 (https=)
TN2015000382A1 (en) Perfluorinated cyclopropyl fused 1,3- oxazin -2- amine compounds as beta- secretase inhibitors and methods of use
DE602004017316D1 (de) Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
JP2013505903A5 (https=)
RU2002128352A (ru) Производные 4,5-дигидро-1н-пиразола, обладающие cb1-антагонистической активностью
JP2013525458A5 (https=)
JP2024517498A5 (https=)
JP2011527686A5 (https=)
JPWO2002010101A1 (ja) アミド化合物を配位子とする遷移金属錯体を用いたアルコールの製造方法
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
NZ590951A (en) Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders
JP2013533253A5 (https=)
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
JP2023509944A5 (https=)
RU2007116987A (ru) Новые соединения